Navigation Links
MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Date:8/19/2007

- Company Further Expands Anti-Interleukin-9 Program with Second Phase 2a

Study -

GAITHERSBURG, Md., Aug. 1 /PRNewswire/ -- MedImmune, Inc. today announced that it has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528.

"We are excited to advance the investigation of this potential treatment for patients with asthma and to further explore the role of IL-9 in the pathology of this disease," said Barbara White, M.D., vice president, clinical development, inflammatory disease. "Recent preclinical study results have provided new insight about IL-9's role in a host of functions associated with the onset of asthma, including allergic inflammation in the airways and allergen-induced airway modeling. These data further support our hypothesis that an antibody blocking IL-9 may represent a new long-term maintenance or controller therapy for symptomatic, persistent asthma."

Two Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. The company is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. MedImmune plans to initiate a third Phase 2a study to evaluate the ability of MEDI-528 to inhibit the biological activity of IL-9 in the bronchoalveolar lavage fluid of adult patients with atopic asthma.

About IL-9

As mentioned above, IL-9 has been associated with symptoms of asthma. It is
'/>"/>

SOURCE MedImmune, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Malvern initiates European user group meetings for chemical imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Lannett Company, Inc. (NYSE: LCI ) today announced ... credit facility to $120 million from $50 million.  The ... the company to increase borrowings by a total of ... additional commitments from existing lenders or new lending institutions.  ... 18, 2018.   "The amended credit facility, ...
(Date:4/24/2015)... , April 24, 2015 Hospira, Inc. ... the development of biosimilar therapies, spoke about the importance ... the European Generics Association (EGA) annual European Biosimilars Group ... The company also announced the publication of a pivotal ... achieving the full promise of biosimilars." ...
(Date:4/24/2015)... CAMBRIDGE, Mass. , April 24, 2015 /PRNewswire/ ... that BLU-554, a selective and potent inhibitor of ... anti-tumor activity in models of hepatocellular carcinoma (HCC) ... targeted therapeutic candidate, BLU-554 induced complete tumor regression ... of an FGFR4-activating ligand at the highest dose ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) announced ... Finance, CFO and treasurer. Mr. Cooper, who has been with ... Company for personal reasons.  He has been commuting from the ... 2006.  Mr. Cooper will remain in his current role at ...
... 2011 Sevocity, a division of Conceptual MindWorks, Inc. ... compliant and was certified as a Complete EHR on ... Information Technology (CCHIT®), an ONC-ATCB, in accordance with the ... of Health and Human Services. The 2011/2012 criteria support ...
Cached Medicine Technology:Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 3Sevocity, a Division of Conceptual MindWorks, Inc's Sevocity Receives ONC-ATCB 2011/2012 Certification 2Sevocity, a Division of Conceptual MindWorks, Inc's Sevocity Receives ONC-ATCB 2011/2012 Certification 3
(Date:4/24/2015)... ON (PRWEB) April 24, 2015 ... safe, informed and legal access to medical cannabis, is ... are properly supported when advising patients. , NAC is ... Certificate Program. With a $250,000 grant, NAC will be ... program. , "Our goal is to help Canadians gain ...
(Date:4/24/2015)... 24, 2015 “ Opera ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how this is ... browsers, surfing the internet would not be in existence. But ... the Opera browser is no different. Celebrating their 20th anniversary ...
(Date:4/24/2015)... Telematics Berlin is the foremost Automotive Data ... 2 suppliers, content providers, associations and government bodies. From ... chain, see them converge in Berlin. This year’s start-up ... those companies currently at the forefront of Europe’s Silicon ... customer centric products, ParkTAG are one of the first ...
(Date:4/24/2015)... Qualis Health, one of the ... a new resource for practicing physicians, “2013 QRUR ... Quality and Resource Use Reports (QRUR) supplements resources ... (CMS) to help practices interpret their Medicare reports ... identify care coordination opportunities to provide broader support ...
(Date:4/24/2015)... York (PRWEB) April 24, 2015 PURE ... with Allergy and Asthma Network (The Network), a highly ... Solutions will provide news, tips and information for a ... Network’s newly redesigned website. , The goal for both ... about the travel needs of people with asthma and ...
Breaking Medicine News(10 mins):Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3Health News:Qualis Health Publishes Guide to Help Physician Practices Assess and Improve Quality 2Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2
... has been selected as one of 10 centers in the ... major new initiative to facilitate the discovery and development of ... Chemical Diversity Centers, Vanderbilt,s role in the consortium will be ... , "This is a real tribute to our growth in ...
... of Pittsburgh School of Medicine have shown that proteins have ... for their biological activity. This shape-changing also allows the small ... the structure that permits the best binding. That premise could ... have the most impact on protein function to better treat ...
... , White paper outlines how to maintain quality ... PLYMOUTH MEETING, Pa., Aug. 19 Physician preference items (PPIs), ... as pricey orthopedic implants and cardiovascular devices, are estimated at 60% ... and margins from both operations and pooled investments declining, many hospital ...
... , , ST. LOUIS, Aug. ... the Mission" on Aug. 15 to raise funds for the company,s ... Approximately 2,400 Reliv independent distributors from 10 countries participated ... place here from Aug. 13-15. , , ...
... 19 N2Care founder Kenneth Dupin presents the MEDcottage to the ... Sheraton Hotel Conference Theater at 2801 Hershberger Rd. in Roanoke, VA ... Kenneth Dupin is throwing down a bedpan gauntlet at the steps ... baby boomers are not going to nursing homes, not ever! On ...
... , SAN RAMON, Calif., Aug. 19 Celebrating ... Hearing Community, Purple Communications((TM)), Inc. (Nasdaq: PRPL ) will ... advocate for American Sign Language (ASL). , , ... 22, 2009 at the San Ramon Marriott, 2600 Bishop Drive in ...
Cached Medicine News:Health News:Vanderbilt joins national consortium to develop new cancer therapies 2Health News:Vanderbilt joins national consortium to develop new cancer therapies 3Health News:Pitt scientists find intrinsic changes in protein shape influence drug binding 2Health News:Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 2Health News:Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 3Health News:Reliv 'Walk for the Mission' Raises Approximately $47,000 for Malnourished People 2Health News:N2Care Unveils Backyard Smart MEDcottage 2Health News:Purple Communications Invites Greater San Ramon Community to Celebrate Ms. Ella Mae Lentz, Finalist in 'Dream Bigger' Initiative 2Health News:Purple Communications Invites Greater San Ramon Community to Celebrate Ms. Ella Mae Lentz, Finalist in 'Dream Bigger' Initiative 3Health News:Purple Communications Invites Greater San Ramon Community to Celebrate Ms. Ella Mae Lentz, Finalist in 'Dream Bigger' Initiative 4Health News:Purple Communications Invites Greater San Ramon Community to Celebrate Ms. Ella Mae Lentz, Finalist in 'Dream Bigger' Initiative 5
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
Agility has delivered a RFID-enabled mobile asset management program....
Agility can provide tracking and management of surgical instruments, instrument trays and case carts to significantly enhance the current central sterile department flow by improving efficiency....
Assetrac allows identification, location, and protection of your assets....
Medicine Products: